Arbutus Biopharma Corporation (ABUS) — Analyst outlook / Analyst consensus target is. Based on 10 analyst ratings, the consensus is bullish — 8 Buy, 2 Hold.
The consensus price target is $8.50, representing an upside of 95.4% from the current price $4.35.
Analysts estimate Earnings Per Share (EPS) of $-0.39 and revenue of $0.01B for the next fiscal year.
Earnings Per Share (EPS) track record: 2024: actual $-0.38 vs est $-0.39 (beat +2.1%). 2025: actual $-0.17 vs est $-0.19 (beat +9.5%). Analyst accuracy: 94%.
ABUS Stock — 12-Month Price Forecast
$8.50
▲ +95.40% Upside
Average Price Target
Based on 10 Wall Street analysts offering 12-month price targets for Arbutus Biopharma Corporation, the price target is $8.50.
The average price target represents a +95.40% change from the last price of $4.35.
ABUS Analyst Ratings
Buy
Based on 10 analysts giving stock ratings to Arbutus Biopharma Corporation in the past 3 months
EPS Estimates — ABUS
94%
Analyst Accuracy
Accurate
2 years compared
Actual vs Estimate
2024
Actual –$0.38
vs Est –$0.39
▲ 2.1% off
2025
Actual –$0.17
vs Est –$0.19
▲ 10.4% off
Profitability Outlook
Company has been making losses in all recent fiscal years. EPS is improving but still negative. Analysts expect losses to continue near-term.
Revenue Estimates — ABUS
98%
Analyst Accuracy
Accurate
2 years compared
Actual vs Estimate
2024
Actual $0.006B
vs Est $0.006B
▼ 0.2% off
2025
Actual $0.014B
vs Est $0.014B
▲ 3.2% off
Revenue Trend
Strong revenue growth over the period shown. Analysts forecast revenue contraction ahead.
